Mesenchymal stem cells‐derived IL ‐6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK‐STAT3 signalling
Oral Diseases · 2024-05 · 30 (4) · 2097-2109
DOI: 10.1111/odi.14617 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 30.05.2023. Verfasst von Chuanxia Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, …. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Interleukin-6, Mesenchymal Stem Cells, Mouth Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Exploration and R&D projects of Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Key Research and Development Program.
Abstract (Originalsprache)
Objectives
Oral squamous cell carcinoma (OSCC) is often diagnosed with cervical lymph node metastasis. Mesenchymal stem cells (MSCs) and interleukin‐6 (IL‐6) signalling are considered to play important roles in promoting tumour malignancy. The detailed biological interaction of MSCs and IL‐6 and the subsequent effect on OSCC metastasis remain largely unclear. This study aimed to determine the effects and molecular mechanism of MSCs‐derived IL‐6 on tumour invasion and metastasis. Subjects and Methods The effects of MSC‐derived IL‐6 and tocilizumab on the proliferation, mobility, and epithelial‐mesenchymal transition (EMT) of OSCC cells and potential pathways were detected in vitro. In addition, a murine xenograft model was generated to verify the biological mechanism in vivo.
Results
The results showed that the expression of MSCs and EMT‐related signals was increased in poorly differentiated OSCC tissues. MSCs released a higher level of IL‐6 and promoted the proliferation, invasion, and metastasis of OSCC cells and solid neoplasms, which were activated by the downstream molecules JAK and STAT3.
Conclusions
The results indicated that MSCs‐derived IL‐6‐promoted tumour invasion and metastasis via JAK–STAT3 signalling. Blockade of this pathway by tocilizumab may be a potential treatment to improve the prognosis and survival rate of patients with OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cance…
- Special Need Clinic, Hangzhou Stomatology Hospital, Hangzhou, China.
ORCID-Profile: Chuanxia Liu, Yilong Hao, Jian Yuan, Qianming Chen
Förderung
- National Natural Science Foundation of China
- Exploration and R&D projects of Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine
- Zhejiang Provincial Key Research and Development Program
- Zhejiang Provincial Medical Health Major Science Project
Zitieren
APA
Liu, C., Zhou, J., Zhang, S., Fu, J., Li, Y., Hao, Y., Yuan, J., Tang, F., Ge, W., He, H., & Chen, Q. (2024). Mesenchymal stem cells‐derived IL ‐6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK‐STAT3 signalling. Oral Diseases, 30(4), 2097-2109. https://doi.org/10.1111/odi.14617
Vancouver
Liu C, Zhou J, Zhang S, Fu J, Li Y, Hao Y, et al. Mesenchymal stem cells‐derived IL ‐6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK‐STAT3 signalling. Oral Diseases. 2024;30(4):2097-2109. doi:10.1111/odi.14617
BibTeX
@article{Liu2024,
author = {Liu, Chuanxia and Zhou, Jinhan and Zhang, Shanshan and Fu, Ji and Li, Yining and Hao, Yilong and Yuan, Jian and Tang, Fan and Ge, Weili and He, Hong and Chen, Qianming},
title = {Mesenchymal stem cells‐derived IL ‐6 promotes invasion and metastasis of oral squamous cell carcinoma via JAK‐STAT3 signalling},
journal = {Oral Diseases},
year = {2024},
volume = {30},
number = {4},
pages = {2097--2109},
doi = {10.1111/odi.14617}
}
EUVIMED